ストックスクリーナーアプリを入手
12.35
1.36%
-0.13
前日終値:
$12.48
開ける：
$12.5
24時間の取引高:
88,858
Relative Volume:
1.68
時価総額：
$4.18B
収益：
$417.75M
当期純損益:
$32.27M
株価収益率:
126.67
EPS:
0.0975
ネットキャッシュフロー:
-
1週間 パフォーマンス:
+3.45%
1か月 パフォーマンス:
-13.31%
6か月 パフォーマンス:
-36.87%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$12.25
$12.50
1週間の範囲:
$10.50
$12.60
52週間の値動き範囲:
$10.50
$30.36
Telix Pharmaceuticals Ltd Adr Stock (TLX) Company Profile
TLX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TLX
Telix Pharmaceuticals Ltd Adr
|
12.35 | 3.98B | 417.75M | 32.27M | 0 | 0.0975 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.22 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
578.96 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
448.54 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
689.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
314.76 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Telix Pharmaceuticals Ltd Adr Stock (TLX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-03 | 開始されました | H.C. Wainwright | Buy |
| 2025-06-05 | 開始されました | Wedbush | Outperform |
| 2024-11-15 | 開始されました | UBS | Buy |
Telix Pharmaceuticals Ltd Adr (TLX) 最新ニュース
Telix 2025 Half-Year Results: Strong commercial performance enables investment for long-term growth - GlobeNewswire Inc.
Telix Pharmaceuticals under SEC investigation for securities fraud, shares plummet. - AInvest
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited – TLX - FinancialContent
Telix Pharmaceuticals Under Investigation for Securities Fraud and Misconduct. - AInvest
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals LimitedTLX - PR Newswire
Pomerantz LLP investigates Telix Pharmaceuticals on securities fraud claims. - AInvest
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited – TLX - FinancialContent
Telix Pharmaceuticals under investigation for potential securities fraud. - AInvest
Bronstein, Gewirtz & Grossman, LLC Is Investigating Telix Pharmaceuticals Limited (TLX) And Encourages Shareholders to Connect - ACCESS Newswire
Telix Pharmaceuticals Limited (TLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Telix Pharmaceuticals under investigation for securities fraud, ADR price falls. - AInvest
Telix Pharmaceuticals Limited (TLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Telix Pharmaceuticals Limited (TLX) And Encourages Investors to Connect - ACCESS Newswire
Telix Pharmaceuticals under investigation for alleged securities fraud. - AInvest
Bronstein, Gewirtz & Grossman, LLC Encourages Telix Pharmaceuticals Limited (TLX) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Telix Announces H1 2025 Earnings Date: Global Investors Briefing Set for August 21 - Stock Titan
Telix Pharmaceuticals Limited (TLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Telix Pharmaceuticals Limited (TLX) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals LimitedTLX - PR Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Telix Pharmaceuticals Limited (TLX) Investors to Inquire about Securities Investigation - ACCESS Newswire
Telix Pharma slides 10% on SEC probe into cancer treatment - Investing.com
Telix Earnings Report: $204M Revenue Crushes Estimates as New Drug Launch Boosts Growth - Stock Titan
Medicare Grants Crucial Reimbursement Code for Telix's Next-Gen Prostate Cancer Imaging Agent - Stock Titan
H.C. Wainwright initiates Telix Pharmaceuticals stock with Buy rating on radiotherapy portfolio - Investing.com
FDA Approval: Illuccix Expansion Could Add 20,000 Annual Prostate Cancer Scans - Stock Titan
Revolutionary Dual-Isotope Cancer Imaging: Telix Unveils AlFluor Platform with Phase 3 Trial Success - Stock Titan
Revolutionary PSMA-PET Imaging Agent Gozellix Transforms Prostate Cancer Detection Across United States - Stock Titan
Leading Cancer Experts Reveal Future of Radiopharmaceuticals at Telix NYC Investor Day - Stock Titan
5 of the best ASX 200 shares to buy in June - The Motley Fool Australia
Telix Leaders Reveal Next-Gen Radiopharmaceutical Pipeline at Exclusive NYC Investor Day - Stock Titan
Telix FAP-targeting Therapeutic Published in Thyroid Journal: Demonstrates Encouraging Efficacy - Stock Titan
Major Breakthrough: France Grants Approval for Advanced Prostate Cancer Detection Technology - Stock Titan
Telix Delivers Record $186M Q1 Revenue as New FDA-Approved Cancer Imaging Agent Bolsters Portfolio - Stock Titan
Breakthrough Brain Cancer Treatment Doubles Survival Time: Phase 2 Results Revealed - Stock Titan
Telix's Groundbreaking Prostate Cancer Imaging Tech Secures Nationwide Distribution Network - Stock Titan
Telix Pharmaceuticals appoints new CTO - Investing.com
Major Board Addition: Ex-GSK and Sanofi Leader Joins Telix Pharmaceuticals - Stock Titan
Revolutionary Cancer Diagnostic Begins Human Trials: First Patient Receives Novel Sarcoma Imaging Agent - Stock Titan
FDA Green Lights Revolutionary Prostate Cancer Detection Tool: What Makes Gozellix a Game-Changer - StockTitan
Telix Pharmaceuticals Limited (ASX:TLX) Receives FDA Approval for Gozellix® - The Capital Club
Paladin Energy Ltd (ASX:PDN) Suspends Operations at Langer Heinrich Mine - The Capital Club
Major Breakthrough: First PSMA-PET Imaging Agent Approved in Brazil's $330M Market - StockTitan
Telix's Game-Changing Isotope Technology Revolutionizes Cancer Treatment Production - StockTitan
Can Telix's Cancer Therapies Transform Urology Treatment? Top Oncologists Weigh In - StockTitan
Could This New Kidney Cancer Imaging Tool Transform Diagnosis? FDA Fast-Tracks Review - StockTitan
Could This New Prostate Cancer Treatment Change Patient Outcomes? Miami Trial Now Recruiting - StockTitan
特斯拉將收購德國Manz部分資產 增強德國自動化實力 - Yahoo 財經
〈強茂展望〉擴大海外布局 越南廠最快2026年量產 - Yahoo 財經
Telix Pharmaceuticals Ltd (TLPPF) (FY 2024) Earnings Call Highlights: Record Revenue Growth and ... By GuruFocus - Investing.com Canada
Can Telix's Triple Product Launch in 2025 Justify Its Bold $1.2B Revenue Target? - StockTitan
Telix Pharmaceuticals Ltd Adr (TLX) 財務データ
収益
当期純利益
現金流量
EPS
0.39%
0.57%
大文字化:
|
ボリューム (24 時間):